Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful faithfully but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the past few shares of mine. My first CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire employment interview which I came away with an inadequate viewpoint of the business.

Irony of irony, the bad viewpoint of mine of the business has grown steadily, yet the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of this technology and also linked intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) and the first new drug application approval ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it has this individual therapies as well as a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic company with diverse interests albeit focused on leronlimab, several disease types, multiple presentations and multiple publications.

Might it all be smoke cigarettes and mirrors? That is a question I have been asking myself from the very beginning of the interest of mine in this organization. Judging by the multiples of thousands of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *